GLP-1 MEDICATIONS Access, Affordability, and What Comes Next Federal Developments At the federal level, the White House announced an agreement in November with Eli Lilly and Novo Nordisk to reduce prices and expand Medicare and Medicaid coverage, including lower prices through direct-to-consumer programs
Wiktelius E, Stenberg G
Check out how much weight you can lose on Ozempic to learn what to expect and find tips to keep your progress steady and safe
announced that approximately 14 of 19 previously restricted peptides reportedly including BPC-157 are expected to be moved back to Category 1 status, which would restore legal compounding pharmacy access
[56] [57] Der Ausschuss fr Risikobewertung im Bereich der Pharmakovigilanz der Europischen Arzneimittel-Agentur (Pharmacovigilance Risk Assessment Committee, PRAC) erklrte im Juni 2025 nach Abschluss der berprfung semaglutidhaltiger Arzneimittel, dass die nicht-arterielle anteriore ischmische Optikusneuropathie (NAION) als eine sehr seltene Nebenwirkung von Semaglutid anzusehen ist (bis zu 1 von 10.000)
Another study a meta-analysis and review of 78 trials involving more than 73,000 participants concluded that semaglutide was associated with an increased incidence of NAION but emphasized that evidence for a causal link remains inconclusive
